John Lozowski
Family Medicine · Phila, PANPI 1063496297
Payments from drug & device makers
Across 155 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$596
- Lilly USA, LLC$474
- GSK$461
- Novo Nordisk$403
- Exact Sciences$143
- Atricure, Inc.$133
- plus $1K from 22 others
What the payments were for
- Speaking & faculty fees$160%
- Food & beverage$3,199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $596 |
| Lilly USA, LLC | 20 | $474 |
| GSK | 24 | $461 |
| Novo Nordisk | 20 | $403 |
| Exact Sciences | 6 | $143 |
| Atricure, Inc. | 1 | $133 |
| Astellas Pharma US Inc | 7 | $128 |
| Boehringer Ingelheim | 6 | $108 |
| Novartis | 5 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $83 |
| Paratek Pharmaceuticals, Inc. | 4 | $81 |
| AstraZeneca | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Pfizer | 2 | $45 |
| Mylan Specialty L.p. | 3 | $43 |
| Viatris Specialty LLC | 2 | $43 |
| Johnson & Johnson | 2 | $41 |
| Merck | 2 | $37 |
| Abbott | 1 | $22 |
| Gilead | 1 | $21 |
| Shield Therapeutics Inc | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,215 in reported general payments places this provider in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $56,173 |
| TrulicityDulaglutide | 36 | $52,106 |
| JardianceEmpagliflozin | 73 | $51,271 |
| FarxigaDapagliflozin Propanediol | 37 | $35,924 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $34,596 |
| EliquisApixaban | 30 | $32,075 |
| GlyxambiEmpagliflozin/Linagliptin | 13 | $22,484 |
| MounjaroTirzepatide | 18 | $20,059 |
| MyrbetriqMirabegron | 33 | $15,726 |
| JanuviaSitagliptin Phosphate | 26 | $15,413 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $11,336 |
| VascepaIcosapent Ethyl | 12 | $4,182 |
| Rosuvastatin Calcium | 125 | $4,110 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $2,551 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 69 | $2,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi | $108 | $73,75686 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $474 | $72,16554 claims |
| Novo NordiskOzempic | $403 | $56,17337 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $73 | $47,26049 claims |
| GSKTrelegy Ellipta | $461 | $34,59641 claims |
| PfizerEliquis | $45 | $32,07530 claims |
| Astellas Pharma US IncMyrbetriq | $128 | $15,72633 claims |
| MerckJanuvia | $37 | $15,41326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Phila
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.